Prometheus founded in 2007, committed to the research, development, production, and sales of in vitro diagnostic reagents. It is the first manufacturer in China to start developing and manufacturing drug abuse products and the first FDA approved manufacturer in Asia. Its products have obtained NMPA registration in China, FDA registration in the United States, and CE registration in Europe. Its leading products are rapid diagnostic products, including five series of drug abuse, women's health, infectious diseases, cardiac markers, and tumor markers.